Format

Send to

Choose Destination
Trends Pharmacol Sci. 2014 Mar;35(3):146-54. doi: 10.1016/j.tips.2013.12.004. Epub 2014 Jan 16.

Small molecule SIRT1 activators for the treatment of aging and age-related diseases.

Author information

1
Department of Genetics, Harvard Medical School, Boston, MA 02115, USA.
2
Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: david_sinclair@hms.harvard.edu.

Abstract

Recent studies in mice have identified single molecules that can delay multiple diseases of aging and extend lifespan. In theory, such molecules could prevent dozens of diseases simultaneously, potentially extending healthy years of life. In this review, we discuss recent advances, controversies, opportunities, and challenges surrounding the development of SIRT1 activators, molecules with the potential to delay aging and age-related diseases. Sirtuins comprise a family of NAD⁺-dependent deacylases that are central to the body's response to diet and exercise. New studies indicate that both natural and synthetic sirtuin activating compounds (STACs) work via a common allosteric mechanism to stimulate sirtuin activity, thereby conferring broad health benefits in rodents, primates, and possibly humans. The fact that two-thirds of people in the USA who consume multiple dietary supplements consume resveratrol, a SIRT1 activator, underscores the importance of understanding the biochemical mechanism, physiological effects, and safety of STACs.

KEYWORDS:

STAC; aging; allosteric activator; cancer; cardiovascular disease; chromatin; deacetylase; diabetes; inflammation; sirtuin

PMID:
24439680
PMCID:
PMC3970218
DOI:
10.1016/j.tips.2013.12.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center